While Bicycle clings to the hope of first-line treatment, Innate eyes a post-Padcev fast track.

JBZ-001, acquired last year, features with CD-001 and ADCE-D01 among recent clinical trial entrants.

Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.

Felmetatug vedotin’s exit could be bad news for Mersana.

The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.

AstraZeneca bags three of the month’s four oncology approvals.

Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.

Firce-1 is scrapped after showing dismal response rates and patient deaths.

Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.

On a wing and a prayer Leap heads for phase 3.